ArticleAdvanced functional materials2022
mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids.
Article in Advanced functional materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 102 citations in OpenAlex.
- Review
- A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Microfluidic-Driven Assembly of RNA Nanocomplexes: Design, Process Control and Translational Perspectives in Oncology.Pharmaceutics · 2026Review
- Electrolyte-driven modulation of charge storage mechanisms in Co metal-organic frameworks for advanced supercapacitors.RSC advances · 2026Article
- Mechanistic insights into mRNA-LNP interactions: role of ionizable lipid content in regulating mRNA intracellular release and translation.Journal of nanobiotechnology · 2026Article
- A hybrid polymeric system for pulmonary mRNA delivery: Advancing mucosal vaccine development.Cell biomaterials · 2026Article
- The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines.Asian journal of pharmaceutical sciences · 2026Review
- Oriented Crystallization of Perovskite Film via Fluorine-Containing Hyperbranched Polymer for Efficient and Stable Perovskite Solar Cells.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Tomatine as a versatile adjuvant boosts mRNA vaccine responses.Materials today. Bio · 2025Article
- Engineering of mRNA vaccine platform with reduced lipids and enhanced efficacy.Nature communications · 2025Article
- Review
- Circular RNA lipid nanoparticle vaccine against SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Rational Design of Unsaturated, Thioether Ionizable Lipids for Enhanced In Vivo mRNA Delivery.Advanced healthcare materials · 2025Article
- Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress.Essays in biochemistry · 2025Review
- Developing mRNA Nanomedicines with Advanced Targeting Functions.Nano-micro letters · 2025Review
- Article
- Piperazine-Derived Bisphosphonate-Based Ionizable Lipid Nanoparticles Enhance mRNA Delivery to the Bone Microenvironment.Angewandte Chemie (International ed. in English) · 2025Article
- Review
- MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses.Bioengineering & translational medicine · 2025Article
- mRNA vaccines as cancer therapies.Chinese medical journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 variants are now still challenging all the approved vaccines, including mRNA vaccines. There is an urgent need to develop new generation mRNA vaccines with more powerful efficacy and better safety against SARS-CoV-2 variants. In this study, a new set of ionizable lipids named 4N4T are constructed and applied to form novel lipid nanoparticles called 4N4T-LNPs. Leading 4N4T-LNPs exhibit much higher mRNA translation efficiency than the approved SM-102-LNPs. To test the effectiveness of the novel delivery system, the DS mRNA encoding the full-length S protein of the SARS-CoV-2 variant is synthesized and loaded in 4N4T-LNPs. The obtained 4N4T-DS mRNA vaccines successfully trigger robust and durable humoral immune responses against SARS-CoV-2 and its variants including Delta and Omicron. Importantly, the novel vaccines have higher RBD-specific IgG titers and neutralizing antibody titers than SM-102-based DS mRNA vaccine. Besides, for the first time, the types of mRNA vaccine-induced neutralizing antibodies are found to be influenced by the chemical structure of ionizable lipids. 4N4T-DS mRNA vaccines also induce strong Th1-skewed T cell responses and have good safety. This work provides a novel vehicle for mRNA delivery that is more effective than the approved LNPs and shows its application in vaccines against SARS-CoV-2 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.